A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck ...

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British ...

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it ...

Scribe Therapeutics has raised close to $129 million in the first initial public offering for a developer of gene editing medicines in more than two years. The startup on Thursday sold 8.58 million ...

Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in ...

While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to ...

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are ...

The startup has a broad global development program underway — and the support of more than 20 investment firms — for a ...

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and ...

A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a ...